Adrenocorticotropic Hormone [ACTH] Market (Source: Natural and Synthetic; Indication: Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2026-2035

Adrenocorticotropic Hormone [ACTH] Market Size and Growth 2026 to 2035

The global adrenocorticotropic hormone [ACTH] market gathered revenue around USD 2.43 billion in 2025 and market is set to grow USD 3.49 billion by the end of 2035 and is estimated to expand at a modest CAGR of 3.7% during the prediction period 2026 to 2035.

Market Key Takeaways

• The global Adrenocorticotropic Hormone (ACTH) market is experiencing steady growth, driven by factors such as an increasing prevalence of ACTH deficiency and related disorders.
• Advances in medical technology, particularly Artificial Intelligence (AI), are beginning to play a transformative role in the market, improving diagnosis and treatment.
• Synthetic ACTH products are dominating the market due to higher efficiency and reliability in treating ACTH deficiency.
• The key challenges to the market include regulatory hurdles, particularly concerning the approval of new ACTH formulations, as well as the high cost of treatment.
• The opportunity for growth lies in the expansion of online pharmacies and telemedicine, particularly in emerging markets.
• North America is currently the largest market, followed closely by Europe, with a promising growth trajectory in the Asia Pacific region.

Market Overview

The global Adrenocorticotropic Hormone (ACTH) market is a crucial segment in the endocrine therapy market. ACTH is a hormone produced by the pituitary gland, and its synthetic versions are widely used to treat various conditions such as adrenal insufficiency, rheumatology diseases, and neurological disorders. The market is predominantly driven by the increasing number of patients diagnosed with ACTH deficiency and diseases that affect the adrenal glands. As healthcare access improves globally, the demand for ACTH-based therapies continues to rise, leading to significant growth in the global market.

ACTH therapies are used in the treatment of disorders such as adrenal insufficiency, rheumatologic conditions like rheumatoid arthritis, and neurological conditions such as multiple sclerosis. With its use spanning multiple therapeutic areas, ACTH's versatility makes it a vital treatment option. The increasing awareness of ACTH deficiency and other adrenal-related diseases, coupled with advancements in pharmaceutical research, continues to drive the market forward.

Market Outlook

• Market Growth Overview: The global adrenocorticotropic hormone (ACTH) market is expected to grow significantly between 2026 and 2035, driven by the rising prevalence of chronic disease, increased awareness, and healthcare infrastructure, and expanding therapeutic applications. 
• Sustainability Trends: Sustainability trends involve the adoption of synthetic alternatives, ethical sourcing and production, and regulatory alignment. 
• Major Investors: Major investors in the market include Mallinckrodt Pharmaceuticals, Pfizer, Inc., Novartis AG, and Merck KGaA.

How is AI Transforming the Adrenocorticotropic Hormone [ACTH] Market?

Artificial Intelligence (AI) is starting to revolutionize several sectors of the healthcare industry, and the ACTH market is no exception. AI technologies are being utilized to optimize drug discovery, personalize treatments, and enhance clinical trials. In the case of ACTH, AI is helping pharmaceutical companies identify new indications and more efficient formulations of ACTH. This allows for faster development of therapies, which is critical for rare diseases like ACTH deficiency.

Furthermore, AI-powered diagnostic tools are improving the early detection of ACTH-related disorders, allowing for timely intervention and better patient outcomes. Machine learning algorithms are being used to analyze patient data and predict the most effective treatment regimens, leading to personalized medicine. AI also helps streamline the drug approval process by analyzing vast datasets to predict regulatory outcomes.

As AI continues to evolve, its role in automating and enhancing the ACTH market will grow, enabling more efficient treatment development and delivery.

Major Trends in the ACTH Market

• Shift Toward Synthetic ACTH: The synthetic ACTH segment is expected to witness strong growth due to its high effectiveness and predictable outcomes in treating ACTH deficiency and related disorders.
• Emerging Markets Growth: Asia Pacific, especially countries like China and India, is witnessing a rise in healthcare access and the adoption of ACTH-based therapies, contributing significantly to market growth.
• Online Pharmacies Expansion: The increasing popularity of online pharmacies, especially in regions like North America and Europe, is providing patients with easier access to ACTH treatments.
• Precision Medicine: The development of precision medicine, fueled by AI, is expected to play a pivotal role in enhancing ACTH therapy customization for patients.
• Research and Development Focus: Pharmaceutical companies are investing heavily in R&D to improve existing ACTH formulations and explore new therapeutic indications.
• Regulatory Challenges: Stringent regulations regarding the approval of new ACTH formulations remain a critical challenge for market players.

Adrenocorticotropic Hormone [ACTH] Market Report Scope

Segmental Insights

By Source

How did the synthetic segment dominate the Global Adrenocorticotropic Hormone (ACTH) market?

The synthetic segment is driven by its superior purity, consistency, and reduced risk of immunogenic reactions compared to natural alternatives. Advances in recombinant technology have enabled cost-effective scalability, allowing manufacturers to meet the high clinical demand for diagnostic and therapeutic applications. Its role as the gold standard for diagnosing adrenal insufficiency and treating infantile spasms makes it highly favored in regulated markets.

By Indication

How did the rheumatology segment account for the largest share in the Global Adrenocorticotropic Hormone (ACTH) market?

The rheumatology segment is driven by the rising prevalence of autoimmune disorders, such as rheumatoid arthritis nd lupus. ACTH serves as a critical long-term therapy for managing chronic inflammation, especially in patients who are unresponsive to traditional corticosteroids. The expanding clinical application across diverse rheumatological practices ensures a consistent and high-volume demand for these therapies.

How did the neurology segment expect to hold the fastest-growing Global Adrenocorticotropic Hormone (ACTH) market in the coming years?

The neurology segment is driven by the development of advanced synthetic analogies with longer half-lives and reduced side effects, making these therapies more attractive for chronic neurological conditions. The ongoing research into new indications like refractory epilepsy and autoimmune encephalitis is rapidly expanding the patient base. This shift towards ACTH as a primary second-line therapy for treatment-resistant cases ensures robust, long-term growth within this clinical vertical.

By Distribution Channel

How did the hospital pharmacies segment account for the largest share in the Global Adrenocorticotropic Hormone (ACTH) market?

The hospital pharmacies segment is driven by the high-stakes nature of managing severe conditions like infantile spasms and MS relapses within inpatient settings. The critical role of hospital pharmacists in monitoring complex drug interactions and side effects makes this channel indispensable for acute and high-risk patient care. The robust healthcare infrastructure in developed regions reinforces the hospital setting as the primary hub for advanced ACTH treatment delivery.

How did the online pharmacies segment expect to hold the fastest-growing Global Adrenocorticotropic Hormone (ACTH) market in the coming years?

The online pharmacies segment is driven by the rapid integration of telehealth and e-prescriptions, which has streamlined the acquisition of high-priced specialty drugs, significantly reducing the logistics burden for patients with limited mobility. By offering a direct-to-consumer model, these platforms bridge the gap for residents in remote areas who require consistent access to critical care. The digitalization of healthcare is fundamentally shifting patient preference away from traditional retail visits toward specialized digital platforms.

Key Players in the Global Adrenocorticotropic Hormone (ACTH) Market

• Mallinckrodt plc ; Mallinckrodt maintains a near-monopoly in the U.S. ACTH market through its flagship product, H.P. Acthar Gel, which is heavily used to treat infantile spasms and other severe autoimmune conditions. 
• Pfizer, Inc.; Pfizer contributes to the global ACTH market by offering Cortrophin Gel, providing a key alternative to Acthar Gel and increasing competitive dynamics in the repository corticotropin injection segment. 
• Novartis AG; Novartis contributes significantly through its development and marketing of Synacthen Depot (tetracosactide), a synthetic form of ACTH that acts as a major competitor, particularly in European markets. 
• Mylan N.V. : Mylan contributes by supplying pharmaceutical-grade active pharmaceutical ingredients (APIs) and participating in the generic segment of the ACTH market. Leveraging its large-scale manufacturing capacity, Mylan enhances the affordability and availability of corticotropin products globally.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the Adrenocorticotropic Hormone [ACTH] market.

By Source

• Natural
• Synthetic

By Indication

• Rheumatology
• Neurology
• Nephrotic Syndrome
• Ophthalmology
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa